Challenges in the Design of a T Cell Vaccine in the Context of HIV-1 Diversity
AbstractThe extraordinary variability of HIV-1 poses a major obstacle to vaccine development. The effectiveness of a vaccine is likely to vary dramatically in different populations infected with different HIV-1 subtypes, unless innovative vaccine immunogens are developed to protect against the range of HIV-1 diversity. Immunogen design for stimulating neutralizing antibody responses focuses on “breadth” – the targeting of a handful of highly conserved neutralizing determinants on the HIV-1 Envelope protein that can recognize the majority of viruses across all HIV-1 subtypes. An effective vaccine will likely require the generation of both broadly cross-neutralizing antibodies and non-neutralizing antibodies, as well as broadly cross-reactive T cells. Several approaches have been taken to design such broadly-reactive and cross-protective T cell immunogens. Artificial sequences have been designed that reduce the genetic distance between a vaccine strain and contemporary circulating viruses; “mosaic” immunogens extend this concept to contain multiple potential T cell epitope (PTE) variants; and further efforts attempt to focus T cell immunity on highly conserved regions of the HIV-1 genome. Thus far, a number of pre-clinical and early clinical studies have been performed assessing these new immunogens. In this review, the potential use of these new immunogens is explored. View Full-Text
Share & Cite This Article
Tongo, M.; Burgers, W.A. Challenges in the Design of a T Cell Vaccine in the Context of HIV-1 Diversity. Viruses 2014, 6, 3968-3990.
Tongo M, Burgers WA. Challenges in the Design of a T Cell Vaccine in the Context of HIV-1 Diversity. Viruses. 2014; 6(10):3968-3990.Chicago/Turabian Style
Tongo, Marcel; Burgers, Wendy A. 2014. "Challenges in the Design of a T Cell Vaccine in the Context of HIV-1 Diversity." Viruses 6, no. 10: 3968-3990.